Podcasts about tiku

Radio Marija ir klausītāju veidots radio, kas nes Dieva Vārdu pasaulē. Radio Marija balss skan 24 stundas diennaktī. Šajos raidījumos klausītājiem kā saviem draugiem neatkarīgi no viņu reliģiskās pārliecības cenšamies sniegt Kristus Labo Vēsti – Evaņģēliju, skaidru katoliskās Baznīcas mācību. Cenšamies vairot lūgšanas pieredzi un sniegt iespēju ielūkoties visas cilvēces kultūras daudzveidībā. Radio Marija visā pasaulē darbojas uz brīvprātīgo kalpošanas pamata. Labprātīga savu talantu un laika ziedošana Dieva godam un jaunās evaņģelizācijas labā ir daļa no Radio Marija harizmas. Tā ir lieliska iespēja ikvienam īstenot savus talantus Evaņģēlija pasludināšanas darbā, piedzīvojot kalpošanas prieku. Ticam, ka Dievs īpaši lietos ikvienu cilvēku, kurš atsauksies šai kalpošanai, lai ar Radio Marija starpniecību paveiktu Latvijā lielas lietas. Radio Marija ir arī ģimene, kas vieno dažādu vecumu, dažādu konfesiju, dažādu sociālo slāņu cilvēkus, ļaujot katram būt iederīgam un sniegt savu pienesumu Dieva Vārda pasludināšanā, kā arī kopīgā lūgšanas pieredzē. "Patvērums Dievā 24 stundas diennaktī", - tā ir Radio Marija Latvija devīze. RML var uztvert Rīgā 97.3, Liepājā 97.1, Krāslavā 97.0, Valkā 93.2, kā arī ar [satelītuztvērēja palīdzību un interneta aplikācijās](http://www.rml.lv/klausies/).

We are now on our 6th pasuk of the pesukim of Shofarot . And it's talking about the shofar that we blow. It's from Tehilim 81,4 תִּקְע֣וּ בַחֹ֣דֶשׁ שׁוֹפָ֑ר בַּ֝כֵּ֗סֶה לְי֣וֹם חַגֵּֽנוּ׃ Blow in the month the Shofar, on the covering of the holiday. The midrash explains that this is one of the hints to blowing the shofar on Rosh Hashanah. It's called the month ( where there's a holiday) when the moon is covered . On other holidays, like Sukkot and Pesach (that are on the 15 th of the month) the moon is very open; and on Shavuot, you see some of the moon. But on first day of the month, you don't see a moon at all. So bakeseh , when the moon is covered, b'chodesh refers to when the new moon is covered , that's when we blow the shofar. The midrash says on this pasuk that on Rosh Hashanah, it doesn't say Tiku shofar b'chodesh/blow the shofar in the month, but rather it says Tiku B'chodesh shofar. The words chodesh and shofar need to be explained in a midrashic approach. Chodesh means chiddush , and shofar means le'sha'per is to beautify. Shifra was the name of the midwife Yocheved because she was mishaperet / she beautified , she cleaned up. So there are two things that we need to do on Rosh Hashanah, Shifru and chidshu . What's the difference? Chidshu means there's certain things that you have to totally renew. This is teshuva . We have to totally renew our acts. We have to stop the bad things we're doing and renew our acts. Rav Wolbe says that's the segula of Rosh Hashanah. At the beginning of a new year, you have the chance to renew yourself and renew your deeds. That's one aspect of Rosh Hashanah. I'm a new person, I'm born again. Adam HaRishon was created,I'm created. And I could start fresh and new. The other aspect is the good things that I'm doing already, that I don't need to do new, but that I can make better . I can smooth them out. I can shine them up. What do these two activities of Chidshu and Shifru do? The midrash continues and says, if you do that, then shofar Teku bachodesh shofar, What does that mean? Just like the shofar is a tube that you blow into on one side and it comes out the other, So too, I am going to have all the complaints against the Jewish people go in through one side and out the other, like the famous saying, In one ear and out the other. The power of the shofar is that we do both these things, we renew and we beautify . That's why we're supposed to be thinking about Teshuva at the time when the shofar blows. This is an important lesson within our shofar pesukim . Rashi, in the sefer Pardes HaGadol, chapter 170 quotes from the Geonim that cite this pasuk as a source that we can't fast on Rosh Hashana, which is called Yom Chaggenu . It's our holiday. Why is it a holiday? We talked about this before, but we'll quote a Seforno in Vayikra 23, 24 that explains that it's a holiday because we're celebrating that He's our king, and when we celebrate that He is our king, He will tilt towards kindness and we will have a good judgment. And he quotes a pasuk in Yeshaya 33, 22 Ki Hashem Shoftenu/God is our judge/Hashem Mechokekenu/He gives us our rules . Hashem Malkenu/Hashem is our King, Hu Yoshienu/He will save us. And that is the holiday. It's a holiday because we're celebrating Hashem's Kingdom and therefore we're going to get a good judgment. He's going to save us. I once saw that there's a custom to sing, especially on Rosh Hashanah after Musaf, En Kelokenu , because on Rosh Hashanah, En Kadonenu/ There's no one like our boss, En Kamalkenu/ There's nobody like our King . En Kemoshi'eno/There's no one like our Savior. And that goes back to this pasuk Hashem Malkeno/ God is my king, Hu Yoshieno/He will save me. On Rosh Hashanah, God is saving us. We don't realize what's going on. On Rosh Hashanah. Its like you just got pulled out of a fiery furnace. You were saved from Gaza. It's feeling of those hostages. That's the feeling of Hu Yoshienu. God is saving us on Rosh Hashanah. We have to celebrate that. It's a great day. Miracles are happening on Rosh Hashanah. And that's a holiday. תִּקְע֣וּ בַחֹ֣דֶשׁ שׁוֹפָ֑ר בַּ֝כֵּ֗סֶה לְי֣וֹם חַגֵּֽנוּ But what makes this holiday happen? What empowers the shofar? Chidshu Shifru - Renew our deeds, beautify our deeds, and celebrate Hashem as our kingdom.

Welcome to Episode 78 of Shirts vs Skins! This week, we dive into the hottest sports topics that are making headlines worldwide.

Daktere Daiga Mūrmane ir medicīnas zinātņu doktore un ārste - ģenētiķe. Viņas klīniskā prakse ir vairāk nekā 20 gadi BKUS un šobrīd RAKUS. Daktere ir bijusi RSU docētāja un ilgstoši Rezidentūras fakultātes studiju programmas "Medicīnas ģenētika" vadītāja. Viņai ir divas specialitātes  - ārste-ģenētiķe un bērnu psihiatre. 2014.gadā viņa aizstāvēja disertāciju par autiskā spektra traucējumu ģenētiskajiem aspektiem un ieguva medicīnas zinātņu doktores grādu. Ikdienā daktere konsultē pacientus ar aizdomām par pārmantotu vēzi.Šo sarunu ar dakteri veidojām, lai mazinātu zaudējumus, ko cilvēkiem nodara nepareizi priekšstati un nezināšana par to, ko gēni nosaka un ko ne. Daktere stāstīja, ka ģenētiskās slimības ir retas un ar ģenētiku mēs mēdzam aizvietot savu nezināšanu, neizdarību, slinkumu - "man tādi gēni". Viņa uzskata, ka tas ir nepareizi, un saka: "Gēns ir tikai gēns. Tā ir iespēja, nevis liktenis. Nevis gēns ietekmē manu dzīvi, bet mana izvēle ietekmē gēna darbību. Tas nozīmē, ka mūsu dzīvesstils, ikdienas izvēles pārtikā un kustībās, stresa menedžments, nevērība pret sevi, savu vajadzību atlikšana var izprovocēt slimības attīstību. Ir ļoti svarīgi runāt par prevenciju, kas ilgtermiņā spēj cilvēkam palīdzēt saglabāt veselību un skaidru prātu. Populācija noveco, bet dzīves kvalitātei, pateicoties mūsdienu tehnoloģijām un iespējām, ir jābūt tādā līmenī, lai es nevis domātu par slimību, bet, būdama vesela, spētu ilgtermiņā baudīt dzīves sniegtās iespējas. Te daudz kas ir atkarīgs no paša izvēles, kā es izturos vai rūpējos par sevi, savu veselību un kas ir mana prioritāte."SARUNAS PIETURPUNKTI:0:00 Ievads3:44 Ko nosaka un ko nenosaka mūsu gēni6:33 Ar ko atšķiras ģenētika no epiģenētikas7:36 Par kurām slimībām var droši teikt, ka tās gēnu dēļ izpaudīsies 100% gadījumu8:31 Lietas, kuras pieņemts uzskatīt par iedzimtām, bet kas nav īsti taisnība12:03 “Tā ir mana atbildība, kā es izvēlos dzīvot”20:47 Dakteres personīgā pieredze ar izdegšanu autiskā spektra ģenētikā un profesionālu “atdzimšanu” no jauna onkoģenētikas nozarē28:06 “Brīdī, kad tu sāc mirt kopā ar pacientu, kaut kas ir jādara”33:50 Cik svarīgi ir katram uzzināt savus “ciltsrakstus” jeb ģimenes slimības vēsturi35:37 “Vēzis nav iesnas vai klepus. Tas nenotiek divu nedēļu laikā” - kādi ir pamata veselības skrīningi vīriešiem un sievietēm37:25 Ko cilvēkam var pateikt viņa onkoloģiskā saslimšana42:13 “Klusie vēži” jeb onkoloģiskās saslimšanas, kuras par sevi dod ziņu tikai vēlīnā stadijā45:43 Kas ir galvenie onkoloģisko saslimšanu ierosinātāji48:49 Kā pēc onkoloģiskās diagnozes savu dzīvi un ikdienu ir mainījusi pati daktere51:39 Kas garšo vēzim57:53 Triki, kā turēties pie veselīgas ēdienkartes arī tad, kad nav vairs tiešu draudu veselībai59:46 “Mums ir jākustas. Stāvošs ūdens glumē. Un mēs esam ūdens”1:02:25 “Mēs šobrīd ēdam par daudz un kustamies par maz. Mums vajadzētu otrādi”1:06:50 Kā daktere trenē savu disciplīnu1:12:17 Psihoterapijas loma cilvēkam, kas saskaras ar nopietniem veselības izaicinājumiem1:13:59 Kāda ir vēderam saistība ar to, kas notiek smadzenēs1:16:41 “Liekais svars ir hronisks iekaisums” – liekā svara ietekme uz laimi un veselību1:20:00 Ārstes – ģenētiķes rekomendācijas par ģenētiskajām analīzēm, kādas un kādos gadījumos ir vērts veikt1:27:22 Paradokss starp bailēm no nāves un bailēm no ārstiem1:28:24 Dakteres personīgā pieredze ar klīnisko nāvi pēc traģiska negadījuma jaunībā1:37:47 Ieteikums nedarīt neko tādu, no kā gēni varētu ciest 

Grabado el 22 de mayo de 2024. En este episodio participan Tiku, Sabio, Ferdopa y [erick]. Tiku nos comenta sus inicios en EOL y le da un repaso junto, Sabio, Ferdopa y [erick] de lo último jugado, visto y leído. Hace pocas fechas Rethen nos comentó la gran pérdida que ha sufrido nuestra comunidad, jiXo abrió un hilo para rendirle un justo homenaje, además muchos amigos de The Cragor lo comentaron por el resto de EOL, en especial en multi, en el mítico hilo HDLQQ. https://www.elotrolado.net/hilo_the-cragor-descansa-en-paz_2501709 Con la ayuda de Tiku recordamos a The Cragor, formó parte del Staff de la web pero es sobre todo recordado por sus tochales, su disponibilidad para ayudar y su forma de hacer comunidad que cautivó a muchos eolianos. Luego abrimos un debate sobre la noticia que público Alejo I: Scarlett Johansson asegura que OpenAI copió su voz sin permiso para su asistente y pide leyes para regular su uso https://www.elotrolado.net/noticias/tecnologia/openai-copio-voz-scarlett-johansson-sin-permiso En el podcast suena un ReMix de Final Fantasy "A Temple of Chaos" por Tim Sheehy https://ocremix.org/remix/OCR00429

Welcome to Episode 71 of the Shirts vs Skins podcast, where hosts Tiku, Ahmed, and Joni unpack the latest and greatest from the world of sports and beyond! Kicking things off, the trio delves into the aftermath of UFC 298, where Henry Cejudo's retirement speech was shockingly denied after his clash with Merab. Join us as we dissect this controversial moment and share our thoughts on what it means for the UFC landscape. Following the UFC review, get ready for a dose of entertainment with our new segment, "Pocket Watching," where Tiku and Ahmed take a swing at ranking athletes by guessing their salaries. It's a hilarious and eye-opening ride you won't want to miss! Next on the agenda, we tackle the buzzing transfer rumors surrounding Kylian Mbappe's potential move to Madrid and delve into Bayern Munich's struggles during the Tuchel era. From transfer drama to on-field challenges, we've got all the insights you need. But wait, there's more! Shirts vs Skins brings back the fan-favorite segment, "Last Man Standing," where two of our hosts go head-to-head in a thrilling trivia game, complete with a side-splitting "Who Am I?" tiebreaker. It's guaranteed fun for all! And finally, we couldn't ignore the elephant in the room: the incredibly lackluster All-Star break in the NBA. Join us as we discuss the league's descent into staleness and explore what it means for the future of basketball entertainment. So grab your headphones and join us for another jam-packed episode of the Shirts vs Skins podcast! Don't forget to like, share, and subscribe for more engaging content. Let's dive in! Don't forget to like, comment and subscribe! Follow us on our social media: Twitter & IG: @ShirtvSkin https://www.instagram.com/shirtvskin/ https://twitter.com/ShirtvSkin Anchor: https://anchor.fm/shirts-vs-skins Youtube: https://youtube.com/channel/UCdS0RhST6UUs6MJr7cI2jCw Apple: https://podcasts.apple.com/us/podcast/shirts-vs-skins/id1522091937Spotify: https://open.spotify.com/show/5ju4iEgfz0C6VgiQoIGJgu Breaker: https://breaker.audio/shirts-vs-skins Pocket Casts: https://pca.st/zw9evfy0 RadioPublic: https://radiopublic.com/shirts-vs-skins-WoqPxx#UFC298 #CejudoRetirement #MbappeMadrid #TuchelSacked #KylianMbappe #SportsPodcast --- Send in a voice message: https://podcasters.spotify.com/pod/show/shirts-vs-skins/message

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/QYG865. CME/MOC/NCPD/AAPA credit will be available until January 21, 2025.Calling Primary Care Partners to Action in Hypertrophic Cardiomyopathy: Shortening the Time to Diagnosis for Improved Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAnjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for BioMarin; Bristol Myers Squibb; Cytokinetics; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics Inc.; and Tenaya Therapeutics.Grant/Research Support from Bristol Myers Squibb.Faculty/PlannerNeil Skolnik, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbott; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Idorsia Pharmaceuticals Ltd; Lilly; Novo Nordisk; Sanofi; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from AstraZeneca; GSK; and Novo Nordisk.Speaker for Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Heartland Pharma; GSK; Lilly; and Teva Pharmaceuticals USA, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/QYG865. CME/MOC/NCPD/AAPA credit will be available until January 21, 2025.Calling Primary Care Partners to Action in Hypertrophic Cardiomyopathy: Shortening the Time to Diagnosis for Improved Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAnjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for BioMarin; Bristol Myers Squibb; Cytokinetics; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics Inc.; and Tenaya Therapeutics.Grant/Research Support from Bristol Myers Squibb.Faculty/PlannerNeil Skolnik, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbott; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Idorsia Pharmaceuticals Ltd; Lilly; Novo Nordisk; Sanofi; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from AstraZeneca; GSK; and Novo Nordisk.Speaker for Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Heartland Pharma; GSK; Lilly; and Teva Pharmaceuticals USA, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/QYG865. CME/MOC/NCPD/AAPA credit will be available until January 21, 2025.Calling Primary Care Partners to Action in Hypertrophic Cardiomyopathy: Shortening the Time to Diagnosis for Improved Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAnjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for BioMarin; Bristol Myers Squibb; Cytokinetics; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics Inc.; and Tenaya Therapeutics.Grant/Research Support from Bristol Myers Squibb.Faculty/PlannerNeil Skolnik, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbott; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Idorsia Pharmaceuticals Ltd; Lilly; Novo Nordisk; Sanofi; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from AstraZeneca; GSK; and Novo Nordisk.Speaker for Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Heartland Pharma; GSK; Lilly; and Teva Pharmaceuticals USA, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/QYG865. CME/MOC/NCPD/AAPA credit will be available until January 21, 2025.Calling Primary Care Partners to Action in Hypertrophic Cardiomyopathy: Shortening the Time to Diagnosis for Improved Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAnjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for BioMarin; Bristol Myers Squibb; Cytokinetics; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics Inc.; and Tenaya Therapeutics.Grant/Research Support from Bristol Myers Squibb.Faculty/PlannerNeil Skolnik, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbott; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Idorsia Pharmaceuticals Ltd; Lilly; Novo Nordisk; Sanofi; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from AstraZeneca; GSK; and Novo Nordisk.Speaker for Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Heartland Pharma; GSK; Lilly; and Teva Pharmaceuticals USA, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/QYG865. CME/MOC/NCPD/AAPA credit will be available until January 21, 2025.Calling Primary Care Partners to Action in Hypertrophic Cardiomyopathy: Shortening the Time to Diagnosis for Improved Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAnjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for BioMarin; Bristol Myers Squibb; Cytokinetics; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics Inc.; and Tenaya Therapeutics.Grant/Research Support from Bristol Myers Squibb.Faculty/PlannerNeil Skolnik, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbott; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Idorsia Pharmaceuticals Ltd; Lilly; Novo Nordisk; Sanofi; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from AstraZeneca; GSK; and Novo Nordisk.Speaker for Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Heartland Pharma; GSK; Lilly; and Teva Pharmaceuticals USA, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/QYG865. CME/MOC/NCPD/AAPA credit will be available until January 21, 2025.Calling Primary Care Partners to Action in Hypertrophic Cardiomyopathy: Shortening the Time to Diagnosis for Improved Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAnjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for BioMarin; Bristol Myers Squibb; Cytokinetics; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics Inc.; and Tenaya Therapeutics.Grant/Research Support from Bristol Myers Squibb.Faculty/PlannerNeil Skolnik, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbott; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Idorsia Pharmaceuticals Ltd; Lilly; Novo Nordisk; Sanofi; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from AstraZeneca; GSK; and Novo Nordisk.Speaker for Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Heartland Pharma; GSK; Lilly; and Teva Pharmaceuticals USA, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/QYG865. CME/MOC/NCPD/AAPA credit will be available until January 21, 2025.Calling Primary Care Partners to Action in Hypertrophic Cardiomyopathy: Shortening the Time to Diagnosis for Improved Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAnjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for BioMarin; Bristol Myers Squibb; Cytokinetics; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics Inc.; and Tenaya Therapeutics.Grant/Research Support from Bristol Myers Squibb.Faculty/PlannerNeil Skolnik, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbott; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Idorsia Pharmaceuticals Ltd; Lilly; Novo Nordisk; Sanofi; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from AstraZeneca; GSK; and Novo Nordisk.Speaker for Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Heartland Pharma; GSK; Lilly; and Teva Pharmaceuticals USA, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/QYG865. CME/MOC/NCPD/AAPA credit will be available until January 21, 2025.Calling Primary Care Partners to Action in Hypertrophic Cardiomyopathy: Shortening the Time to Diagnosis for Improved Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAnjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for BioMarin; Bristol Myers Squibb; Cytokinetics; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics Inc.; and Tenaya Therapeutics.Grant/Research Support from Bristol Myers Squibb.Faculty/PlannerNeil Skolnik, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbott; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Idorsia Pharmaceuticals Ltd; Lilly; Novo Nordisk; Sanofi; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from AstraZeneca; GSK; and Novo Nordisk.Speaker for Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Heartland Pharma; GSK; Lilly; and Teva Pharmaceuticals USA, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

You've heard of six-minute abs, but how about the 15-minute orgasm? That's what Nicole Daedone of OneTaste was touting; female empowerment through clitoris stimulation. Then like most high-demand groups, things go south pretty quickly. In this Strange Country episode, co hosts Beth and very uncomfortable Kelly talk about the rise and fall of OneTaste. Theme music: Big White Lie by A Cast of Thousands. Cite your sources: Brown, Mick. “Inside Hollywood's Orgasm Cult - LAmag - Culture, Food, Fashion, News & Los Angeles.” Los Angeles Magazine, 26 May 2022, https://lamag.com/news/inside-hollywoods-orgasm-cult. Accessed 10 December 2023.   Canner, Liz, director. Orgasm Inc: The Story of OneTaste. First Run Features, 2022. Netflix.   Cohen, Luc. “US founder of 'orgasmic meditation' company charged with forced labor conspiracy.” Reuters, 6 June 2023, https://www.reuters.com/business/onetaste-sexual-wellness-executives-charged-by-us-with-forced-labor-2023-06-06/. Accessed 10 December 2023.   Ferriss, Timothy. The 4-Hour Body: An Uncommon Guide to Rapid Fat-Loss, Incredible Sex, and Becoming Superhuman. Harmony/Rodale, 2010.   Gross, Rachel E. Vagina Obscura: An Anatomical Voyage. WW Norton, 2022.   Huet, Ellen, et al. “The Dark Side of the Orgasmic Meditation Company.” Bloomberg.com, 18 June 2018, https://www.bloomberg.com/news/features/2018-06-18/the-dark-side-of-onetaste-the-orgasmic-meditation-company. Accessed 10 December 2023.   James, Emma. “'Orgasmic meditation cult' OneTaste SUES Netflix for defamation.” Daily Mail, 28 November 2023, https://www.dailymail.co.uk/news/article-12781527/Orgasmic-meditation-cult-OneTaste-SUES-Netflix-defamation.html. Accessed 10 December 2023.   Meko, Hurubie. “Founder of Sexual Wellness Company Indicted on Forced Labor Charges.” The New York Times, 6 June 2023, https://www.nytimes.com/2023/06/06/nyregion/one-taste-commune-nicole-daedone-indicted.html. Accessed 10 December 2023.   Meyer, Robinson, and Ashley Fetters. “Victorian Doctors Didn't Treat Women With Orgasms, Say Historians.” The Atlantic, 6 September 2018, https://www.theatlantic.com/health/archive/2018/09/victorian-vibrators-orgasms-doctors/569446/. Accessed 2 December 2023.   Morin, Roc. “Inside the Implosion of OneTaste, San Francisco's Orgasmic Meditation Cult,.” Playboy, 9 October 2018, https://www.playboy.com/read/one-taste-orgasmic-meditation. Accessed 12 December 2023.   “OneTaste Founder and Former Head of Sales Indicted for Forced Labor Conspiracy.” Department of Justice, 6 June 2023, https://www.justice.gov/usao-edny/pr/onetaste-founder-and-former-head-sales-indicted-forced-labor-conspiracy. Accessed 10 December 2023.   Peltz, Jennifer. “OneTaste founder pleads not guilty in forced labor case.” Fortune, 14 June 2023, https://fortune.com/2023/06/14/nicole-daedone-onetaste-entrepreneur-promoted-orgasmic-meditation-route-woman-health-pleads-not-guilty-forced-labor-case/. Accessed 10 December 2023.   Pogash, Carol. “In San Francisco, a Coed Retreat Dedicated to Female Sexuality.” The New York Times, 13 March 2009, https://www.nytimes.com/2009/03/15/fashion/15commune.html?searchResultPosition=2. Accessed 11 December 2023.   Tiku, Nitasha. “My life with the thrill-clit cult.” Cult Education Institute, Originally published to Gawker, 16 October 2013, https://www.culteducation.com/group/1373-onetaste/26847-my-life-with-the-thrill-clit-cult.html. Accessed 10 December 2023.   “View Exhibit.” N I N E S - View Exhibit, https://nines.org/exhibits/Victorian_Anxiety_Over_Female_?page=2. Accessed 2 December 2023.

Go online to PeerView.com/UBM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease, with a mortality rate estimated to be about three times greater than that experienced by individuals of similar age without HCM. So far, the FDA has approved only one noninvasive treatment option indicated for the treatment of HCM—a first-in-class cardiac myosin inhibitor (CMI) called mavacamten. A second CMI, aficamten, is currently being studied. As timely diagnosis of patients with HCM may reduce or delay the need for invasive treatment, these treatment options are essential for cardiologists to understand. This PeerView activity covers what you need to know about diagnosing and managing HCM for optimal patient care. A patient case threads through each section and offers a window into real-world diagnostic and treatment challenges as our expert shares guidance and the latest evidence. By the end of this activity, you will be able to explain the underlying pathophysiology of HCM, apply your new knowledge for timely diagnosis and individualized treatment of HCM, and implement strategies for long-term patient safety and improved outcomes. Upon completion of this activity, participants should be better able to: Apply current guidance and the latest evidence to support accurate differential diagnosis and encourage early treatment in patients suspected of having HCM; Evaluate the efficacy and safety evidence supporting the ability of modern targeted strategies to address the underlying pathophysiology of HCM; Individualize treatment of HCM based on patients' personal preferences and goals of care and identify opportunities to reduce inequities; and Implement strategies that encourage and support regular assessment of clinical status, LVEF, and LVOT gradient in patients with HCM, consulting with specialty colleagues as needed.

Go online to PeerView.com/UBM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease, with a mortality rate estimated to be about three times greater than that experienced by individuals of similar age without HCM. So far, the FDA has approved only one noninvasive treatment option indicated for the treatment of HCM—a first-in-class cardiac myosin inhibitor (CMI) called mavacamten. A second CMI, aficamten, is currently being studied. As timely diagnosis of patients with HCM may reduce or delay the need for invasive treatment, these treatment options are essential for cardiologists to understand. This PeerView activity covers what you need to know about diagnosing and managing HCM for optimal patient care. A patient case threads through each section and offers a window into real-world diagnostic and treatment challenges as our expert shares guidance and the latest evidence. By the end of this activity, you will be able to explain the underlying pathophysiology of HCM, apply your new knowledge for timely diagnosis and individualized treatment of HCM, and implement strategies for long-term patient safety and improved outcomes. Upon completion of this activity, participants should be better able to: Apply current guidance and the latest evidence to support accurate differential diagnosis and encourage early treatment in patients suspected of having HCM; Evaluate the efficacy and safety evidence supporting the ability of modern targeted strategies to address the underlying pathophysiology of HCM; Individualize treatment of HCM based on patients' personal preferences and goals of care and identify opportunities to reduce inequities; and Implement strategies that encourage and support regular assessment of clinical status, LVEF, and LVOT gradient in patients with HCM, consulting with specialty colleagues as needed.

Go online to PeerView.com/UBM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease, with a mortality rate estimated to be about three times greater than that experienced by individuals of similar age without HCM. So far, the FDA has approved only one noninvasive treatment option indicated for the treatment of HCM—a first-in-class cardiac myosin inhibitor (CMI) called mavacamten. A second CMI, aficamten, is currently being studied. As timely diagnosis of patients with HCM may reduce or delay the need for invasive treatment, these treatment options are essential for cardiologists to understand. This PeerView activity covers what you need to know about diagnosing and managing HCM for optimal patient care. A patient case threads through each section and offers a window into real-world diagnostic and treatment challenges as our expert shares guidance and the latest evidence. By the end of this activity, you will be able to explain the underlying pathophysiology of HCM, apply your new knowledge for timely diagnosis and individualized treatment of HCM, and implement strategies for long-term patient safety and improved outcomes. Upon completion of this activity, participants should be better able to: Apply current guidance and the latest evidence to support accurate differential diagnosis and encourage early treatment in patients suspected of having HCM; Evaluate the efficacy and safety evidence supporting the ability of modern targeted strategies to address the underlying pathophysiology of HCM; Individualize treatment of HCM based on patients' personal preferences and goals of care and identify opportunities to reduce inequities; and Implement strategies that encourage and support regular assessment of clinical status, LVEF, and LVOT gradient in patients with HCM, consulting with specialty colleagues as needed.

Go online to PeerView.com/UBM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease, with a mortality rate estimated to be about three times greater than that experienced by individuals of similar age without HCM. So far, the FDA has approved only one noninvasive treatment option indicated for the treatment of HCM—a first-in-class cardiac myosin inhibitor (CMI) called mavacamten. A second CMI, aficamten, is currently being studied. As timely diagnosis of patients with HCM may reduce or delay the need for invasive treatment, these treatment options are essential for cardiologists to understand. This PeerView activity covers what you need to know about diagnosing and managing HCM for optimal patient care. A patient case threads through each section and offers a window into real-world diagnostic and treatment challenges as our expert shares guidance and the latest evidence. By the end of this activity, you will be able to explain the underlying pathophysiology of HCM, apply your new knowledge for timely diagnosis and individualized treatment of HCM, and implement strategies for long-term patient safety and improved outcomes. Upon completion of this activity, participants should be better able to: Apply current guidance and the latest evidence to support accurate differential diagnosis and encourage early treatment in patients suspected of having HCM; Evaluate the efficacy and safety evidence supporting the ability of modern targeted strategies to address the underlying pathophysiology of HCM; Individualize treatment of HCM based on patients' personal preferences and goals of care and identify opportunities to reduce inequities; and Implement strategies that encourage and support regular assessment of clinical status, LVEF, and LVOT gradient in patients with HCM, consulting with specialty colleagues as needed.

Go online to PeerView.com/UBM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease, with a mortality rate estimated to be about three times greater than that experienced by individuals of similar age without HCM. So far, the FDA has approved only one noninvasive treatment option indicated for the treatment of HCM—a first-in-class cardiac myosin inhibitor (CMI) called mavacamten. A second CMI, aficamten, is currently being studied. As timely diagnosis of patients with HCM may reduce or delay the need for invasive treatment, these treatment options are essential for cardiologists to understand. This PeerView activity covers what you need to know about diagnosing and managing HCM for optimal patient care. A patient case threads through each section and offers a window into real-world diagnostic and treatment challenges as our expert shares guidance and the latest evidence. By the end of this activity, you will be able to explain the underlying pathophysiology of HCM, apply your new knowledge for timely diagnosis and individualized treatment of HCM, and implement strategies for long-term patient safety and improved outcomes. Upon completion of this activity, participants should be better able to: Apply current guidance and the latest evidence to support accurate differential diagnosis and encourage early treatment in patients suspected of having HCM; Evaluate the efficacy and safety evidence supporting the ability of modern targeted strategies to address the underlying pathophysiology of HCM; Individualize treatment of HCM based on patients' personal preferences and goals of care and identify opportunities to reduce inequities; and Implement strategies that encourage and support regular assessment of clinical status, LVEF, and LVOT gradient in patients with HCM, consulting with specialty colleagues as needed.

Go online to PeerView.com/UBM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease, with a mortality rate estimated to be about three times greater than that experienced by individuals of similar age without HCM. So far, the FDA has approved only one noninvasive treatment option indicated for the treatment of HCM—a first-in-class cardiac myosin inhibitor (CMI) called mavacamten. A second CMI, aficamten, is currently being studied. As timely diagnosis of patients with HCM may reduce or delay the need for invasive treatment, these treatment options are essential for cardiologists to understand. This PeerView activity covers what you need to know about diagnosing and managing HCM for optimal patient care. A patient case threads through each section and offers a window into real-world diagnostic and treatment challenges as our expert shares guidance and the latest evidence. By the end of this activity, you will be able to explain the underlying pathophysiology of HCM, apply your new knowledge for timely diagnosis and individualized treatment of HCM, and implement strategies for long-term patient safety and improved outcomes. Upon completion of this activity, participants should be better able to: Apply current guidance and the latest evidence to support accurate differential diagnosis and encourage early treatment in patients suspected of having HCM; Evaluate the efficacy and safety evidence supporting the ability of modern targeted strategies to address the underlying pathophysiology of HCM; Individualize treatment of HCM based on patients' personal preferences and goals of care and identify opportunities to reduce inequities; and Implement strategies that encourage and support regular assessment of clinical status, LVEF, and LVOT gradient in patients with HCM, consulting with specialty colleagues as needed.

Please visit answersincme.com/PBR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in managing hypertrophic cardiomyopathy (HCM) discuss best practices for diagnosis and evidence-based strategies using cardiac myosin inhibitors. Upon completion of this activity, participants should be better able to: Identify best practices to optimally diagnose patients with HCM in order to improve patient outcomes; Describe the clinical impact of cardiac myosin inhibitors in managing patients with obstructive HCM; and Outline practical strategies to incorporate cardiac myosin inhibitors into treatment plans for patients with obstructive HCM.

Ladies and gentlemen, get ready to immerse yourselves in the enchanting world of Bollywood! Welcome to "Mumbai Raj," the ultimate podcast channel where we dive into the glitz, glamour, and endless drama of Hindi cinema.From show reviews to juicy gossip, from behind-the-scenes secrets to epic movie discussions, "Mumbai Raj" is your one-stop destination for everything Bollywood. Join me as we embark on a rollercoaster ride through the colorful lanes of Mumbai's film industry. Expect witty banter, hilarious anecdotes, and engaging conversations with Bollywood and industry insiders.Whether you're a die-hard fan of romantic sagas, high-octane action, or soul-stirring melodies, "Mumbai Raj" has got you covered. Together, we'll explore the fascinating world of Bollywood movies, dissecting the plots, analyzing the performances, and unraveling the hidden gems.So, grab your popcorn, put on your dancing shoes, and get ready to experience Bollywood like never before! From the iconic classics to the latest blockbusters, "Mumbai Raj" will be your guide through the glimmering galaxy of stars, where fun and mischief are always on the menu.Disclaimer: The views and opinions expressed in this podcast are solely those of the host and guests and do not necessarily reflect the official policies or positions of "Mumbai Raj."

We started the week with Social Currency on Netflix where we struggled to keep our sanity, Kafas on SonyLiv was hard to watch yet gripping. Kangana Ranaut's Tiku Weds Sheru on Netflix was weirdly unsatisfying and World's Best on Disney was a joy to watch.This was our week. How was yours?LoveTeam Desis.Desislive podcast delivers the latest movie and show reviews to your devices. Wherever in the world you are, tune in to desislive.

Tiku Weds Sheru, the new rom-com/crime drama starring Nawazuddin Siddiqui and Avneet Kaur, sent us into an existential spiral. We wonder how Kangana Ranaut could make her film production debut with something as pedestrian as this, and come up with conspiracy theories for how Siddiqui and Prime Video would agree to associate themselves with this movie. We also talk about its jarring tonal shifts, its complete inauthenticity, and its refusal to be sincere about what it wants to be. — Hosted by Akhil Arora and Rohan Naahar, The Long Take is fully bootstrapped. Please consider donating if you enjoy our work. The Long Take is available on Spotify, Apple Podcasts, Amazon Music, Gaana, JioSaavn, Overcast, Stitcher, RadioPublic, Google Podcasts, and wherever you get your podcasts. Follow The Long Take on Facebook, Twitter, Instagram, and YouTube. Write to us at thelongtakepod@gmail.com. --- Support this podcast: https://podcasters.spotify.com/pod/show/the-long-take/support

An SvS special matchup of Miami Heat vs New York Knicks has begun in the NBA Playoffs, and Ahmed and Tiku are READY! 0:00 Intro 1:02 Shit Takes 20:30 NBA Playoffs 37:15 Miami Heat vs NY Knicks 56:00 Athlete Comparisons 1:02:00 Arsenal's Demise Follow us on our social media: Twitter & IG: @ShirtvSkin https://www.instagram.com/shirtvskin/ https://twitter.com/ShirtvSkin --- Send in a voice message: https://podcasters.spotify.com/pod/show/shirts-vs-skins/message

Go online to PeerView.com/GYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease and has a mortality rate estimated to be about three times greater than that experienced by individuals of similar age without HCM. The FDA has recently approved a noninvasive, first-in-class cardiac myosin inhibitor specifically indicated for the treatment of HCM—meaning timely diagnosis of patients with HCM may reduce or delay the need for invasive treatment. In this activity, based on a recent live symposium, expert panelists present practical skills and guidance to accurately diagnose HCM and apply recent treatment advances to patients with various clinical presentations of HCM. They begin by sharing the rationale for maintaining a high index of suspicion for HCM and review diagnostic strategies. The Clinical Consults portion of this activity features case examples to demonstrate current practices in diagnosis and offer practical guidance for treating patients—focusing on personalized care with new and emerging therapeutic options. Concluding with an engaging Q&A, this activity is for anyone involved in the care of patients with HCM interested in loosening the grip of this increasingly treatable disease. Upon completion of this activity, participants should be better able to: Suspect the presence of HCM based on clinical symptoms, pathologic features, and/or family history; Differentially diagnose patients suspected of having HCM consistent with current guidance to promote early diagnosis and timely treatment; and Individualize treatment for patients with HCM based on the efficacy, safety, and potential ability of the therapeutic strategy to address the underlying disease pathophysiology.

Go online to PeerView.com/GYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease and has a mortality rate estimated to be about three times greater than that experienced by individuals of similar age without HCM. The FDA has recently approved a noninvasive, first-in-class cardiac myosin inhibitor specifically indicated for the treatment of HCM—meaning timely diagnosis of patients with HCM may reduce or delay the need for invasive treatment. In this activity, based on a recent live symposium, expert panelists present practical skills and guidance to accurately diagnose HCM and apply recent treatment advances to patients with various clinical presentations of HCM. They begin by sharing the rationale for maintaining a high index of suspicion for HCM and review diagnostic strategies. The Clinical Consults portion of this activity features case examples to demonstrate current practices in diagnosis and offer practical guidance for treating patients—focusing on personalized care with new and emerging therapeutic options. Concluding with an engaging Q&A, this activity is for anyone involved in the care of patients with HCM interested in loosening the grip of this increasingly treatable disease. Upon completion of this activity, participants should be better able to: Suspect the presence of HCM based on clinical symptoms, pathologic features, and/or family history; Differentially diagnose patients suspected of having HCM consistent with current guidance to promote early diagnosis and timely treatment; and Individualize treatment for patients with HCM based on the efficacy, safety, and potential ability of the therapeutic strategy to address the underlying disease pathophysiology.

Go online to PeerView.com/GYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease and has a mortality rate estimated to be about three times greater than that experienced by individuals of similar age without HCM. The FDA has recently approved a noninvasive, first-in-class cardiac myosin inhibitor specifically indicated for the treatment of HCM—meaning timely diagnosis of patients with HCM may reduce or delay the need for invasive treatment. In this activity, based on a recent live symposium, expert panelists present practical skills and guidance to accurately diagnose HCM and apply recent treatment advances to patients with various clinical presentations of HCM. They begin by sharing the rationale for maintaining a high index of suspicion for HCM and review diagnostic strategies. The Clinical Consults portion of this activity features case examples to demonstrate current practices in diagnosis and offer practical guidance for treating patients—focusing on personalized care with new and emerging therapeutic options. Concluding with an engaging Q&A, this activity is for anyone involved in the care of patients with HCM interested in loosening the grip of this increasingly treatable disease. Upon completion of this activity, participants should be better able to: Suspect the presence of HCM based on clinical symptoms, pathologic features, and/or family history; Differentially diagnose patients suspected of having HCM consistent with current guidance to promote early diagnosis and timely treatment; and Individualize treatment for patients with HCM based on the efficacy, safety, and potential ability of the therapeutic strategy to address the underlying disease pathophysiology.

Go online to PeerView.com/GYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease and has a mortality rate estimated to be about three times greater than that experienced by individuals of similar age without HCM. The FDA has recently approved a noninvasive, first-in-class cardiac myosin inhibitor specifically indicated for the treatment of HCM—meaning timely diagnosis of patients with HCM may reduce or delay the need for invasive treatment. In this activity, based on a recent live symposium, expert panelists present practical skills and guidance to accurately diagnose HCM and apply recent treatment advances to patients with various clinical presentations of HCM. They begin by sharing the rationale for maintaining a high index of suspicion for HCM and review diagnostic strategies. The Clinical Consults portion of this activity features case examples to demonstrate current practices in diagnosis and offer practical guidance for treating patients—focusing on personalized care with new and emerging therapeutic options. Concluding with an engaging Q&A, this activity is for anyone involved in the care of patients with HCM interested in loosening the grip of this increasingly treatable disease. Upon completion of this activity, participants should be better able to: Suspect the presence of HCM based on clinical symptoms, pathologic features, and/or family history; Differentially diagnose patients suspected of having HCM consistent with current guidance to promote early diagnosis and timely treatment; and Individualize treatment for patients with HCM based on the efficacy, safety, and potential ability of the therapeutic strategy to address the underlying disease pathophysiology.

Go online to PeerView.com/GYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease and has a mortality rate estimated to be about three times greater than that experienced by individuals of similar age without HCM. The FDA has recently approved a noninvasive, first-in-class cardiac myosin inhibitor specifically indicated for the treatment of HCM—meaning timely diagnosis of patients with HCM may reduce or delay the need for invasive treatment. In this activity, based on a recent live symposium, expert panelists present practical skills and guidance to accurately diagnose HCM and apply recent treatment advances to patients with various clinical presentations of HCM. They begin by sharing the rationale for maintaining a high index of suspicion for HCM and review diagnostic strategies. The Clinical Consults portion of this activity features case examples to demonstrate current practices in diagnosis and offer practical guidance for treating patients—focusing on personalized care with new and emerging therapeutic options. Concluding with an engaging Q&A, this activity is for anyone involved in the care of patients with HCM interested in loosening the grip of this increasingly treatable disease. Upon completion of this activity, participants should be better able to: Suspect the presence of HCM based on clinical symptoms, pathologic features, and/or family history; Differentially diagnose patients suspected of having HCM consistent with current guidance to promote early diagnosis and timely treatment; and Individualize treatment for patients with HCM based on the efficacy, safety, and potential ability of the therapeutic strategy to address the underlying disease pathophysiology.

Go online to PeerView.com/GYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease and has a mortality rate estimated to be about three times greater than that experienced by individuals of similar age without HCM. The FDA has recently approved a noninvasive, first-in-class cardiac myosin inhibitor specifically indicated for the treatment of HCM—meaning timely diagnosis of patients with HCM may reduce or delay the need for invasive treatment. In this activity, based on a recent live symposium, expert panelists present practical skills and guidance to accurately diagnose HCM and apply recent treatment advances to patients with various clinical presentations of HCM. They begin by sharing the rationale for maintaining a high index of suspicion for HCM and review diagnostic strategies. The Clinical Consults portion of this activity features case examples to demonstrate current practices in diagnosis and offer practical guidance for treating patients—focusing on personalized care with new and emerging therapeutic options. Concluding with an engaging Q&A, this activity is for anyone involved in the care of patients with HCM interested in loosening the grip of this increasingly treatable disease. Upon completion of this activity, participants should be better able to: Suspect the presence of HCM based on clinical symptoms, pathologic features, and/or family history; Differentially diagnose patients suspected of having HCM consistent with current guidance to promote early diagnosis and timely treatment; and Individualize treatment for patients with HCM based on the efficacy, safety, and potential ability of the therapeutic strategy to address the underlying disease pathophysiology.

Go online to PeerView.com/GYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease and has a mortality rate estimated to be about three times greater than that experienced by individuals of similar age without HCM. The FDA has recently approved a noninvasive, first-in-class cardiac myosin inhibitor specifically indicated for the treatment of HCM—meaning timely diagnosis of patients with HCM may reduce or delay the need for invasive treatment. In this activity, based on a recent live symposium, expert panelists present practical skills and guidance to accurately diagnose HCM and apply recent treatment advances to patients with various clinical presentations of HCM. They begin by sharing the rationale for maintaining a high index of suspicion for HCM and review diagnostic strategies. The Clinical Consults portion of this activity features case examples to demonstrate current practices in diagnosis and offer practical guidance for treating patients—focusing on personalized care with new and emerging therapeutic options. Concluding with an engaging Q&A, this activity is for anyone involved in the care of patients with HCM interested in loosening the grip of this increasingly treatable disease. Upon completion of this activity, participants should be better able to: Suspect the presence of HCM based on clinical symptoms, pathologic features, and/or family history; Differentially diagnose patients suspected of having HCM consistent with current guidance to promote early diagnosis and timely treatment; and Individualize treatment for patients with HCM based on the efficacy, safety, and potential ability of the therapeutic strategy to address the underlying disease pathophysiology.

Go online to PeerView.com/GYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease and has a mortality rate estimated to be about three times greater than that experienced by individuals of similar age without HCM. The FDA has recently approved a noninvasive, first-in-class cardiac myosin inhibitor specifically indicated for the treatment of HCM—meaning timely diagnosis of patients with HCM may reduce or delay the need for invasive treatment. In this activity, based on a recent live symposium, expert panelists present practical skills and guidance to accurately diagnose HCM and apply recent treatment advances to patients with various clinical presentations of HCM. They begin by sharing the rationale for maintaining a high index of suspicion for HCM and review diagnostic strategies. The Clinical Consults portion of this activity features case examples to demonstrate current practices in diagnosis and offer practical guidance for treating patients—focusing on personalized care with new and emerging therapeutic options. Concluding with an engaging Q&A, this activity is for anyone involved in the care of patients with HCM interested in loosening the grip of this increasingly treatable disease. Upon completion of this activity, participants should be better able to: Suspect the presence of HCM based on clinical symptoms, pathologic features, and/or family history; Differentially diagnose patients suspected of having HCM consistent with current guidance to promote early diagnosis and timely treatment; and Individualize treatment for patients with HCM based on the efficacy, safety, and potential ability of the therapeutic strategy to address the underlying disease pathophysiology.

BONUS CONTENTPatreon: https://www.patreon.com/MFTIC?fan_landing=trueRokfin: https://www.rokfin.com/myfamilythinksimcrazySubstack: https://myfamilythinksimcrazy.substack.com/Synchro-Wisdom Dialogue: https://linktr.ee/mysticmarkpodcastKo-fi: https://ko-fi.com/myfamilythinksimcrazyMerch: https://mftic-podcast.creator-spring.comHelp fund the show, I cannot do this without your support.CashApp: $MarkSteevesJrVenmo: @MysticMarkPaypal: @mysticmarkBuy Me A Coffee: https://www.buymeacoffee.com/MFTICWithout you this Podcast would not exist, may good karma bless all who support.Roman Merrell, Co-host of Rising From The Ashes, invited me to join him in interviewing Doctor Michael E. Bell. We discussed Dr. Bell's book Food For The Dead, how folklore holds valuable information about human culture and how man has reconciled with and understood disease's like Tuberculosis as recently as 200 years ago. Only since the invention of Microscope have we had clear indications of a possible microscopic explanation for disease, nonetheless faith healing, folk medicine and arcane rituals persist in human culture. Consumption as it was known in the early days of American history, was often blamed on a vampiric disembodied evil that manifested its evil upon the living and siphoned vital energies into a nearby corpse usually of a known relative who recently perished to consumption themselves. Roman and I asked Dr. Bell many questions about folklore and Paracelsian medicine. Learn more from Doctor Bell, buy his book Food For The Dead via any major book retailer. Support the Homie Romie on Patreon and subscribe to his podcast Rising From The Ashes. This Episode's Artwork was created by Tiku follow him @Tikunkit @eyekonok on Instagram.Share This Episode: https://share.transistor.fm/s/ed39e59bThis Podcast is Sponsored by the Hit Kit! check out the Hit Kit Here  https://hitkit.us/New Booklet by Mystic MarkS.E.E.E.N. #2 N.E.M.M.E.S.S.I.S.S. Buy Nowhttps://ko-fi.com/s/9baa70f625MFTIC MerchJoin us on TelegramLeave me a message On Telegram!For Exclusive My Family Thinks I'm Crazy Content: Only 5$ get 150+ Bonus Episodes, Sign up on our Patreon For Exclusive Episodes. Check out the S.E.E.E.N.or on Rokfin@MFTICPodcast on Twitter@myfamilythinksimcrazy on Instagram, Follow, Subscribe, Rate, and Review we appreciate you!https://www.myfamilythinksimcrazy.comhttps://altmediaunited.com/my-family-thinks-im-crazy/Listen to Every AMU Podcast with this link. https://lnns.co/pI5xHeyFdfgGET A NEW PODCASTING APP! https://podcastindex.org/appsMUSICAL CREDITSMusic: DruidBy Wicked CinemaMusic: SinisterBy Ghost BeatzOutroMusic: Piano Concerto No 21 in C Major/As I DreamBy MomentsMusic: Soul TrapBy Tao ShuReleased under a Creative Commons Attribution International 4.0 License Thanks To Soundstripe and FMA CC4.0 ★ Support this podcast on Patreon ★

BONUS CONTENTPatreon: https://www.patreon.com/MFTIC?fan_landing=trueRokfin: https://www.rokfin.com/myfamilythinksimcrazySubstack: https://myfamilythinksimcrazy.substack.com/Synchro-Wisdom Dialogue: https://linktr.ee/mysticmarkpodcastKo-fi: https://ko-fi.com/myfamilythinksimcrazyMerch: https://mftic-podcast.creator-spring.comHelp fund the show, I cannot do this without your support.CashApp: $MarkSteevesJrVenmo: @MysticMarkPaypal: @mysticmarkBuy Me A Coffee: https://www.buymeacoffee.com/MFTICWithout you this Podcast would not exist, may good karma bless all who support.John Brisson, of Fix Your Gut and We've Read The Documents, joins me to discuss his research into the factions behind the NWO and the globalists who are worshipping a Luciferian theosophy. John shares his thoughts and opinions on The Finders and their similarities with Discordian Groups.  I asked John about the factions vying for the throne and how their agenda is wrapped up in occultism and ancient religious notions. John shared with me the term Multi-Polar World Order and how a Russian chaos magician inspired the Tartaria craze sweeping alternative culture. John relayed his experiences with Gnosticism and Occultism and why he decided to leave that behind to become a Born Again Baptist Christian.This Episode's Artwork was created by Tiku follow him @Tikunkit @eyekonok on Instagram. Share This Episode: https://share.transistor.fm/s/e60e3ee9This Podcast is Sponsored by the Hit Kit! check out the Hit Kit Here  https://hitkit.us/New Booklet by Mystic MarkS.E.E.E.N. #2 N.E.M.M.E.S.S.I.S.S. Buy Nowhttps://ko-fi.com/s/9baa70f625MFTIC MerchJoin us on TelegramLeave me a message On Telegram!For Exclusive My Family Thinks I'm Crazy Content: Only 5$ get 150+ Bonus Episodes, Sign up on our Patreon For Exclusive Episodes. Check out the S.E.E.E.N.or on Rokfin@MFTICPodcast on Twitter@myfamilythinksimcrazy on Instagram, Follow, Subscribe, Rate, and Review we appreciate you!https://www.myfamilythinksimcrazy.comhttps://altmediaunited.com/my-family-thinks-im-crazy/Listen to Every AMU Podcast with this link. https://lnns.co/pI5xHeyFdfgGET A NEW PODCASTING APP! https://podcastindex.org/appsMUSICAL CREDITSMusic: WolgrimBy Cody MartinOutroMusic: Rise/Standing On The Edge/Two MotionsBy Stephen KeechMusic: Soul TrapBy Tao ShuReleased under a Creative Commons Attribution International 4.0 License Thanks To Soundstripe and FMA CC4.0 ★ Support this podcast on Patreon ★

Joni and Tiku accept Messi as the GOAT, NY NFL Football is getting closer and closer to playoffs, and Ahmed thinks the NBA needs a new commissioner. Enjoy the newest segment: justify your take, with hilarious results. Follow us on our social media: Twitter & IG: @ShirtvSkin https://www.instagram.com/shirtvskin/ https://twitter.com/ShirtvSkin Apple: https://podcasts.apple.com/us/podcast/shirts-vs-skins/id1522091937 Spotify: https://open.spotify.com/show/5ju4iEgfz0C6VgiQoIGJgu Google Podcasts: https://google.com/podcasts?feed=aHR0cHM6Ly9hbmNob3IuZm0vcy8yODQ2NjkzYy9wb2RjYXN0L3Jzcw== Breaker: https://breaker.audio/shirts-vs-skins Pocket Casts: https://pca.st/zw9evfy0 RadioPublic: https://radiopublic.com/shirts-vs-skins-WoqPxx Youtube: https://youtube.com/channel/UCdS0RhST6UUs6MJr7cI2jCw --- Send in a voice message: https://anchor.fm/shirts-vs-skins/message

Beidzot esam tikuši pie jaunās valdības - kāds ir šo divarpus mēnešu sarunu rezultāts? Ko varam sagaidīt tālāk? Vēl - strīdi Rīgas domē un korupcijas skandāls Briselē. Aktualitātes vērtē "ReTV" galvenā redaktore Inga Gorbunova, aģentūras LETA žurnāliste Anastasija Tetarenko-Supe un TV24 raidījuma "Nacionālo interešu klubs" vadītajs Romāns Meļņiks.  

The Round of 16 of Qatar 2022 brought us some entertaining football, with the Quarterfinals to come, SvS gives their picks. Ahmed and Tiku draft up their top 5 in the NFL race for MVP, and celebrate Judge's extension with the Yankees. UFC 282 is this weekend, and the lads give their prediction and share excitement over Bryce Mitchell vs Topuria. Follow us on our social media: Twitter & IG: @ShirtvSkin https://www.instagram.com/shirtvskin/ https://twitter.com/ShirtvSkin Apple: https://podcasts.apple.com/us/podcast/shirts-vs-skins/id1522091937 Spotify: https://open.spotify.com/show/5ju4iEgfz0C6VgiQoIGJgu Google Podcasts: https://google.com/podcasts?feed=aHR0cHM6Ly9hbmNob3IuZm0vcy8yODQ2NjkzYy9wb2RjYXN0L3Jzcw== Breaker: https://breaker.audio/shirts-vs-skins Pocket Casts: https://pca.st/zw9evfy0 RadioPublic: https://radiopublic.com/shirts-vs-skins-WoqPxx Youtube: https://youtube.com/channel/UCdS0RhST6UUs6MJr7cI2jCw #WorldCup #Portugal #GoncaloRamos #SvS #SportsPodcast #Podcast #Sports #MMA #Football #Soccer #NBA #Basketball #MLB #Baseball #Cricket #Tennis #F1 #Rugby #Volleyball #Darts #ShirtsVsSkins #Shirts #Skins #versus #vs #ufc --- Send in a voice message: https://anchor.fm/shirts-vs-skins/message

Go online to PeerView.com/KHN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on hypertrophic cardiomyopathy (HCM) discusses guideline-recommended diagnostic approaches and therapeutic strategies to improve symptoms and preserve quality of life. Upon completion of this activity, participants should be better able to: Recognize the clinical characteristics and pathologic features suggestive of HCM; Differentially diagnose patients suspected of having HCM consistent with current guidance and evidence to promote early diagnosis and timely treatment; Assess the efficacy, safety, and ability of available therapeutic strategies to address the underlying pathophysiology and desired treatment goals; and Individualize treatment regimens for HCM consistent with patient preferences and goals of care.

Go online to PeerView.com/KHN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on hypertrophic cardiomyopathy (HCM) discusses guideline-recommended diagnostic approaches and therapeutic strategies to improve symptoms and preserve quality of life. Upon completion of this activity, participants should be better able to: Recognize the clinical characteristics and pathologic features suggestive of HCM; Differentially diagnose patients suspected of having HCM consistent with current guidance and evidence to promote early diagnosis and timely treatment; Assess the efficacy, safety, and ability of available therapeutic strategies to address the underlying pathophysiology and desired treatment goals; and Individualize treatment regimens for HCM consistent with patient preferences and goals of care.

Go online to PeerView.com/KHN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on hypertrophic cardiomyopathy (HCM) discusses guideline-recommended diagnostic approaches and therapeutic strategies to improve symptoms and preserve quality of life. Upon completion of this activity, participants should be better able to: Recognize the clinical characteristics and pathologic features suggestive of HCM; Differentially diagnose patients suspected of having HCM consistent with current guidance and evidence to promote early diagnosis and timely treatment; Assess the efficacy, safety, and ability of available therapeutic strategies to address the underlying pathophysiology and desired treatment goals; and Individualize treatment regimens for HCM consistent with patient preferences and goals of care.

Go online to PeerView.com/KHN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on hypertrophic cardiomyopathy (HCM) discusses guideline-recommended diagnostic approaches and therapeutic strategies to improve symptoms and preserve quality of life. Upon completion of this activity, participants should be better able to: Recognize the clinical characteristics and pathologic features suggestive of HCM; Differentially diagnose patients suspected of having HCM consistent with current guidance and evidence to promote early diagnosis and timely treatment; Assess the efficacy, safety, and ability of available therapeutic strategies to address the underlying pathophysiology and desired treatment goals; and Individualize treatment regimens for HCM consistent with patient preferences and goals of care.

Go online to PeerView.com/KHN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on hypertrophic cardiomyopathy (HCM) discusses guideline-recommended diagnostic approaches and therapeutic strategies to improve symptoms and preserve quality of life. Upon completion of this activity, participants should be better able to: Recognize the clinical characteristics and pathologic features suggestive of HCM; Differentially diagnose patients suspected of having HCM consistent with current guidance and evidence to promote early diagnosis and timely treatment; Assess the efficacy, safety, and ability of available therapeutic strategies to address the underlying pathophysiology and desired treatment goals; and Individualize treatment regimens for HCM consistent with patient preferences and goals of care.

Go online to PeerView.com/KHN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on hypertrophic cardiomyopathy (HCM) discusses guideline-recommended diagnostic approaches and therapeutic strategies to improve symptoms and preserve quality of life. Upon completion of this activity, participants should be better able to: Recognize the clinical characteristics and pathologic features suggestive of HCM; Differentially diagnose patients suspected of having HCM consistent with current guidance and evidence to promote early diagnosis and timely treatment; Assess the efficacy, safety, and ability of available therapeutic strategies to address the underlying pathophysiology and desired treatment goals; and Individualize treatment regimens for HCM consistent with patient preferences and goals of care.

Tiku, Ahmed, and Joni discuss the results of March Madness, Wrestlemania 38 and the surprisingly incredible celebrity matches, UFC 273 preview, and rounding off the episode with a controversial comments. Follow us on our social media: Twitter & IG: @ShirtvSkin https://www.instagram.com/shirtvskin/ https://twitter.com/ShirtvSkin Apple: https://podcasts.apple.com/us/podcast/shirts-vs-skins/id1522091937 Spotify: https://open.spotify.com/show/5ju4iEgfz0C6VgiQoIGJgu Google Podcasts: https://google.com/podcasts?feed=aHR0cHM6Ly9hbmNob3IuZm0vcy8yODQ2NjkzYy9wb2RjYXN0L3Jzcw== Breaker: https://breaker.audio/shirts-vs-skins Pocket Casts: https://pca.st/zw9evfy0 RadioPublic: https://radiopublic.com/shirts-vs-skins-WoqPxx Youtube: https://youtube.com/channel/UCdS0RhST6UUs6MJr7cI2jCw --- Send in a voice message: https://anchor.fm/shirts-vs-skins/message

This week you guys are in for a treat. Two beautiful women from different cultures . Different backgrounds . Different traditions found sisterhood , found a tribe on a mountain top . Studied abroad and traveled the world together . Started careers outside of their hometown and for a full circle meant they are back at home again , in the basement . I have the pleasure of introducing these inspirational women , Tiku & Francheska. Topics: - Traveling - Culture/heritage - AmerriKKKa - Share your voice Tiku, the Cameroon Goddess & Francheska, the Philippina princess share what it was like growing up as immigrants/ minorities in this country. They talk family dynamic and the love they have for their culture . Lots of laughs and lots to learn . As Always Drink Your Water & Mind Your Business ! NEW EPISODES EVERY TUESDAY ! --- Support this podcast: https://anchor.fm/aightsooboomthepodcast/support

                                                                Vikas Tiku explains why you should "listen more than you speak", why once you've made a decision you shouldn't second guess" and that "your career highlights will never make it to your tombstone" along with seven other great lessons. Hosted by Siebe Van Der Zee. About Vikas Tiku Vikas has over 30 years of experience with large, global businesses in the US, Asia Pacific, and Africa. Vikas served as Representative Director, Head of Transformation, Chief Financial, and Strategy Officer for Coca-Cola Bottlers Japan Holdings Inc. He was voted as the ‘Best CFO in Japan' (Food & Beverage sector) by Investor Weekly publication in 2018. Vikas started his professional career with The Pillsbury Company. He subsequently served as COO and CFO for Source Precision Medicine; a start-up medical technologies company based in Colorado. He joined The Coca-Cola Company in 2005 as M&A Lead for Asia Pacific before going on to serve as CFO Africa (2006-2008), CFO Japan (2009-2014), and CFO Asia Pacific (2015-2016). Vikas has a Bachelor of Electronics and Electrical Communication Engineering degree from Punjab University in India and an MBA from the University of Minnesota. He attended the Advanced Management Program at Harvard Business School in Spring 2019   Episode Notes  Lesson 1: What brought you here isn't necessarily going to get you there. 5m 26s Lesson 2: Be true to who you are. Be authentic 09m 09s Lesson 3: Decide quickly when stakes are not high…Decide carefully when stakes are high 12m 28s Lesson 4: Create possibilities and don't close options too quickly…they have value 18m 33s Lesson 5: Conflict by itself isn't good or bad. Your reaction makes it so 25m 16s Lesson 6: Listen more than you speak 30m 44s Lesson 7: Your career highlights will never make it to your tombstone 34m 27s Lesson 8: Once you've made a choice don't second guess 38m 42s Lesson 9: You can't do something without actually doing it. 41m 44s Lesson 10: Be Humble. Nobody knows everything 44m 07s

Get into the cockpit of a Jaguar with Gp. Capt. Ajit Agtey in Part 2 of this two-part interview, and hear about the trials leading to Initial Operational Clearance for the DARIN Jaguar. In that you'll learn how he won a case of Champagne from a French engineer. He also talks about his experiences fitting AN-12 engines on an AN-32 and other test flying experiences.You can read more about the DARIN in this wonderful blog post by Air Cmde TK "Tiku" Sen -- https://tkstales.wordpress.com/2010/03/07/the-darin-story/